Treatment progress of elderly acute myeloid leukemia:reports from the 57th American Society of Hematology annual meeting / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 79-82, 2016.
Article
en Zh
| WPRIM
| ID: wpr-487737
Biblioteca responsable:
WPRO
ABSTRACT
Elderly acute myeloid leukemia (AML) accounted for 35 % of all AML with the increased incidence year by year, and the median onset age is 67 years old. Generally, AML patients require strong chemotherapy, but older patients often cannot tolerate intense chemotherapy due to the viscera dysfunction. It is still lack of unified treatment clinically. Reports on treatment of elderly AML in the 57th American Society of Hematology (ASH) annual meeting covered multiple fields, in which the traditional induction chemotherapy, demethylation drug alone or in combination with other drugs, and novel drugs were an involved. This article reviewed the latest research on the elderly AML in the 57th ASH annual meeting.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Año:
2016
Tipo del documento:
Article